Immunization with multiple vaccine modalities induce strong HIV-specific cellular and humoral immune responses

Viral Immunology

Volumn 25, Issue 5, 2012, Pages 423-432

  Hallengärd, David ^a   Applequist, Steven E ^a   Nyström, Sanna ^a   Maltais, Anna Karin ^a   Marovich, Mary ^b   Moss, Bernard ^c   Earl, Patricia ^c   Nihlmark, Kopek ^d   Wahren, Britta ^a   Bråve, Andreas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d National Institutes of Health ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; RECOMBINANT GP140C; RECOMBINANT MODIFIED VACCINIA ANKARA ENCODING HIV ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; ELECTROPORATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN;

AIDS VACCINES; ANIMALS; DNA, VIRAL; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; INTERLEUKIN-2; MICE; MICE, INBRED BALB C; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

MUS;

EID: 84867204828     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0046     Document Type: Article

References (46)

1. Bakari M, Aboud S, Nilsson C, et al.: Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011;29:8417-8428.
2. Hill AV, Reyes-Sandoval A, O'Hara G, et al.: Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010;6:78-83.
3. Kent SJ, Zhao A, Best SJ, et al.: Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72:10180-10188.
4. Koup RA, Roederer M, Lamoreaux L, et al.: Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010;5:e9015.
5. Vaine M, Wang S, Hackett A, et al.: Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010;28:2999-3007.
6. Brave A, Boberg A, Gudmundsdotter L, et al.: A new multiclade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8( + ) T-cell and humoral responses in mice. Mol Ther 2007;15:1724-1733.
7. Sandstrom E, Nilsson C, Hejdeman B, et al.: Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008;198:1482-1490.
8. Wang S, Kennedy JS, West K, et al.: Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008;26:3947-3957.
9. Pitisuttithum P, Gilbert P, Gurwith M, et al.: Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006;194:1661-1671.
10. Sandstrom E, and Wahren B: Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999;353:1735-1742.
11. Deeks SG, and Walker BD: Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27:406-416.
12. Kiepiela P, Ngumbela K, Thobakgale C, et al.: CD8 + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007;13:46-53.
13. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
14. Rowland-Jones SL, Dong T, Fowke KR, et al.: Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.
15. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
16. Shiver JW, Fu TM, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
17. De Rosa SC, Thomas EP, Bui J, et al.: HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol 2011;187: 3391-3401.
18. Harari A, Bart PA, Stohr W, et al.: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77.
19. Jaoko W, Karita E, Kayitenkore K, et al.: Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One 2010;5:e12873.
20. Barnett SW, Rajasekar S, Legg H, et al.: Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997;15:869-873.
21. Cristillo AD, Wang S, Caskey MS, et al.: Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006; 346:151-168.
22. Richmond JF, Lu S, Santoro JC, et al.: Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998;72:9092-9100.
23. Wang S, Arthos J, Lawrence JM, et al.: Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JRFL primary isolate of human immunodeficiency virus type. J Virol 2005;79:7933-7937.
24. Wang S, Pal R, Mascola JR, et al.: Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006;350:34-47.
25. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
26. Nakamura GR, Fonseca DP, O'Rourke SM, et al.: Monoclonal antibodies to the V2 domain of MN-rgp120: Fine mapping of epitopes and inhibition of alpha4beta7 binding. PLoS One 2012;7:e39045.
27. Brave A, Ljungberg K, Boberg A, et al.: Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005;12:1197-1205.
28. Earl PL, Cotter C, Moss B, et al.: Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009;27:5885-5895.
29. Cranage MP, Fraser CA, Stevens Z, et al.: Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses. Mucosal Immunol 2010;3:57-68.
30. Roos AK, Eriksson F, Timmons JA, et al.: Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226.
31. Isaguliants MG, Petrakova NN, Zuber B, et al.: DNA-encoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 2000;43:288-293.
32. Kjerrstrom A, Hinkula J, Engstrom G, et al.: Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 2001;284:46-61.
33. Ljungberg K, Rollman E, Eriksson L, et al.: Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002;302:44-57.
34. Brave A, Ljungberg K, Boberg A, et al.: Reduced cellular immune responses following immunization with a multigene HIV-1 vaccine. Vaccine 2006;24:4524-4526.
35. Hallengard D, Haller BK, Maltais AK, et al.: Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 2011;18: 1577-1581.
36. Hallengard D, Haller BK, Petersson S, et al.: Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 2011;29: 839-848.
37. Ohlin M, Hinkula J, Broliden PA, et al.: Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol 1992;89:290-295.
38. Hutchings CL, Gilbert SC, Hill AV, and Moore AC: Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 2005;175:599-606.
39. Miao J, Li X, Liu Z, et al.: Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Vaccine 2006;24:6187-6198.
40. Buge SL, Ma HL, Amara RR, et al.: Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 2003;19:891-900.
41. Brave A, Hallengard D, Gudmundsdotter L, et al.: Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine 2009;27:3692-3696.
42. Vasan S, Hurley A, Schlesinger SJ, et al.: In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011; 6:e19252.
43. Mazumder S, Maji M, Das A, and Ali N: Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice. PLoS One 2011;6:e14644.
44. Wang QM, Sun SH, Hu ZL, et al.: Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting. Vaccine 2004;22:3622-3627.
45. Delaloye J, Roger T, Steiner-Tardivel QG, et al.: Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009;5:e1000480.
46. Barouch DH, O'Brien KL, Simmons NL, et al.: Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010;16: 319-323.